Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carvedilol + simvastatin
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carvedilol + simvastatin is a combination therapy that pairs two medications with complementary cardiovascular benefits. Carvedilol is a non-selective beta-adrenergic antagonist with additional alpha-1 blocking properties, used to treat heart failure, left ventricular dysfunction, and hypertension. Simvastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol production in the liver, treating hyperlipidemia and reducing cardiovascular risk. Studies have shown that this combination therapy may have additive beneficial effects on cardiovascular outcomes, particularly in patients with left ventricular dysfunction after myocardial infarction. The combination has demonstrated improved survival rates, reduced major adverse cardiovascular events (MACE), and enhanced portal pressure reduction in patients with liver cirrhosis compared to monotherapy with either agent.
- Brand names
- ZocorCoregDilatrend
- Other names
- Simvastatin and Carvedilol combination therapySimvastatin/Carvedilol
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ADRB1 (β1)ADRB2 (β2)ADRA1A (α1A)
Beyond the preview
Go deeper on carvedilol + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carvedilol + simvastatin.